All Topics

Healthcare M&A in Canada is experiencing a significant transformation, with total deal values surging from $4.5 billion to over $12 billion as pharmaceutical companies navigate patent cliffs and pursue revenue-generating assets. As artificial intelligence reshapes transaction assessments and intellectual property diligence becomes increasingly complex, dealmakers must adopt multidisciplinary approaches that integrate regulatory, data governance, and technology considerations into their strategic evaluations